• CervoMed completed enrollment in a Phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia, a form of frontotemporal dementia.
• Trial enrolled 25 participants on oral dosing for 24 weeks, followed by a 12-week randomized, double-blind, placebo-controlled extension.
• Interim biomarker data slated for presentation at the CTAD conference in November 2026; first biomarker readout expected early Q4 2026.
• First clinical data expected in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on July 09, 2026, and is solely responsible for the information contained therein.